Four UCLB spinout companies are named finalists in the European Lifestars Awards

We are delighted to announce that four UCLB spinout companies have been named finalists for the 2019 European Lifestars Awards.

Ixico has been shortlisted for the Healthtech Company of the year award. The company provides image analysis services to healthcare providers and the pharmaceutical industry.

Orchard Therapeutics has been shortlisted for IPO of the year award.  The biopharmaceutical company is based on research arising from the groups of Professors Bobby Gaspar and Adrian Thrasher, at the UCL Institute of Child Health. In November last year it raised $225million through its initial public offering.

Quell Therapeutics has been shortlisted for Series A finance raise of the year award. Quell was established earlier this year, with the aim of developing engineered T regulatory (Treg) cell therapies.

Autolus therapeutics has been shortlisted post IPO raise of the year award.  The a clinical-stage biopharmaceutical company is developing next-generation programmed T cell therapies for the treatment of cancer.

The winners of each category will be revealed at the awards ceremony on November 19^th 2019 at the Honourable Artillery Company in London.

Find out more about European Lifestars Awards 2019.